A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult to treat types of breast cancer. Here, a phase 2 clinical trial in TNBC patients reveals that the addition of lobaplatin to docetaxel and epirubicin regime improves pCR and ORR rates with tolerable side-effects.

Guardado en:
Detalles Bibliográficos
Autores principales: Xiujuan Wu, Peng Tang, Shifei Li, Shushu Wang, Yueyang Liang, Ling Zhong, Lin Ren, Ting Zhang, Yi Zhang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/7abdbe810517401892ad3cece4d6b05b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares